Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | MMP8 | P22894 | 4/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815343 | 0.87 | MIF (0.46) | KMT2AMIF | |
| SCHEMBL346094 | 0.87 | CA1 (0.53) | KMT2ACA1CA2ACHEDRD2 | |
| SCHEMBL344552 | 0.87 | CA1 (0.53) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL4016019 | 0.85 | KMT2A (0.47) | KMT2ACA1CA2 | |
| SCHEMBL5859196 | 0.83 | KMT2A (0.48) | KMT2AACHE | |
| SCHEMBL5858918 | 0.81 | KMT2A (0.47) | KMT2ACA1CA2 | |
| SCHEMBL388601 | 0.81 | MTNR1A (0.54) | KMT2ACA1CA2ACHEDRD2 | |
| SCHEMBL18989955 | 0.81 | KMT2A (0.47) | KMT2ACA1CA2MMP8MMP3 | |
| SCHEMBL1340597 | 0.81 | KMT2A (0.47) | KMT2AACHE | |
| SCHEMBL29443104 | 0.81 | KMT2A (0.47) | KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647710-B2 | Thiazole derivative and applications thereof | MEDSHINE DISCOVERY INC. (CN) | 2020-05-12 | — | — | US | disclosed |
| EP-3566749-A1 | THIAZOLE DERIVATIVE AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2670245-B1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | SCRIPPS RESEARCH INST (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2670245-B1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | SCRIPPS RESEARCH INST (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| CN-103980235-A | GPR120 receptor agonists and uses thereof | CYMABAY THERAPEUTICS INC | 2014-08-13 | — | — | CN | disclosed |
| WO-2011159297-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011159297-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2367793-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KMT2A 2862/4885CA1 4868/4885CA2 3472/4885 |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KMT2A 2862/4885CA1 4868/4885CA2 3472/4885 |
| US-10647710-B2 | Thiazole derivative and applications thereof | TSLP, TK2, TK1 | KMT2A 4236/4885CA1 3642/4885CA2 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.